Last reviewed · How we verify
GW823296 tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GW823296 tablet (GW823296 tablet) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GW823296 tablet TARGET | GW823296 tablet | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GW823296 tablet CI watch — RSS
- GW823296 tablet CI watch — Atom
- GW823296 tablet CI watch — JSON
- GW823296 tablet alone — RSS
Cite this brief
Drug Landscape (2026). GW823296 tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/gw823296-tablet. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab